Pelotonia is a grassroots bike tour with one goal: to end cancer
Not Yet Registered?
If you have not yet registered to participate in Pelotonia 14, click here to register as a Rider, Virtual Rider, or Volunteer.
Close Tab

Where The Money Goes

Funds raised by Pelotonia riders help Ohio State researchers

100%… Of All Funds Raised…

by Pelotonia Riders, Virtual Riders and Volunteers directly supports cancer research at the Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute (OSUCCC-James). Pelotonia dollars support four key areas at Ohio State’s cancer program; The Pelotonia Fellowship Program, Idea Grants, Tools for Discovery and Bringing the Best to Ohio State.

The Pelotonia Fellowship Program

The Pelotonia Fellowship Program trains promising and accomplished undergraduate, graduate, medical and postdoctoral students from any discipline at Ohio State who have the potential to become independent cancer researchers. The Fellowship Program started in 2010 and to date has awarded 225 student fellowships through an annual allocation of 2 million in Pelotonia revenue for this program. Scholarship recipients so far include.

  • 99 undergraduates
  • 59 graduates
  • 4 medical students
  • 48 postdoctoral fellows
  • 15 international scholars

Most recently, from October 2012- October 2013, the program awarded 58 fellowships to students at all levels of scholarship for conducting cancer research in the labs of faculty mentors. Recipients included 25 undergrads, 15 graduate students, one medical student, 11 postdoctoral fellows and six international scholars.  Visit the Pelotonia Fellowship Program for more information.

Idea Grants

It is unlikely that a cure for cancer will come from one scientist. Instead, it will be through “team science” that we will get new answers and treatments. With this in mind, the Pelotonia Research Award Program provided two-year “idea” grants that enable creative teams of scientists at Ohio State to embark on research that could lead to discoveries resulting in better treatments and prevention strategies. Pelotonia dollars boosted team science at the OSUCCC- James in 2013 by supporting nine idea grants and one protocol-specific research (PSR) grant. The grants were awarded to teams of faculty researchers who are pursuing early work in basic, clinical/ translational  or population science that could lead to larger grants from external sources. These grants are especially important because government funding is difficult to obtain for the early pursuit of innovative ideas. The grants were awarded by a scientific review committee of external and internal reviewers that was chaired by the OSUCCC associate directors. The committee considered the scientific merit of competitive applications submitted by the research teams.

The 2014 Pelotonia Idea Grants 

Delivering an AML Drug in ‘Nano-sized Fat Bubbles’

Acute myelogeneous leukemia (AML) affects more than 14,500 Americans annually and has a poor survival rate. The drug bortezomib has potential to help AML patients, but it is only weakly effective against leukemia in its current form. In this project, an OSUCCC-James team from the colleges of engineering, medicine and pharmacy will develop a novel delivery system for this medication by packing the drug into nanosized bubbles of fat and attaching it to a homing device that seeks out leukemia cells, sparing healthy cells. Preliminary studies suggest this approach effectively targets leukemia cells and results in lower drug toxicities. Data from the study will determine whether this approach is suitable for testing in humans.

Social Isolation’s Role in Breast Cancer Development and Progression

Studies show that women with breast cancer who are socially isolated have worse clinical outcomes. This OSUCCC-James team will examine whether loneliness and isolation alter cancer-related gene activity in breast tissue. The study investigates a molecular mechanism by which the social environment influences breast cancer initiation and progression. The team hypothesizes that a tumor-suppressor gene called PTEN plays a significant role in this process. Information from this study could reveal potential new diagnostic, therapeutic and prognostic tools for breast cancer prevention and treatment. Breast tissue for this study will be obtained from women undergoing biopsy at the Stefanie Spielman Comprehensive Breast Center for possible breast cancer.

Mental Health, Stress and the Response to Cancer Treatment

Chronic lymphocytic leukemia (CLL) is the most prevalent form of adult leukemia and is currently incurable. This project will assess stress, depression and quality of life in patients receiving an effective new treatment called ibrutinib, which has been studied extensively in clinical trials at The OSUCCC – James. This study examines the relationship between cancer growth factors and patient psychological function. This information could help physicians make treatment decisions by identifying patients at risk for poor outcomes.

Biomaker-Based Two-Drug Therapy for Acute Myeloid Leukemia

Overall survival is low for both pediatric and adult patients with acute myeloid leukemia (AML) on standard chemotherapy. This study is a phase I (first-in-human) clinical trial to test a two-drug approach that could significantly increase remission in AML patients. Initial studies conducted at This OSUCCC – James, have shown that the drug decitabine is well tolerated in older AML patients and can achieve a 47 percent remission rate. Additionally, patients with higher levels of a substance in the blood called miR-29b had a better response to decitabine than those with lower levels. A second drug, known as AR-42, which was developed by OSUCCC – James researchers, increases levels of miR-29b in leukemia cells. This clinical trial will administer AR-42 first to AML patients as a way to increase miR-29b levels in the blood and possibly improve the effectiveness of decitabine therapy. The findings evaluate an innovative strategy for increasing the number of AML patients who achieve complete remission.

Studying Health Disparities in 100,000-Under-served in America

Despite an overall decrease in cancer incidence and death in many populations, significant health disparities exist in low income, racial and ethnic minority, rural, immigrant, under and uninsured and low-educated populations. This project will establish a cohort of 100,000 under-served people to better understand the causes of cancer disparities in the United States. The cohort will focus on four under-served population groups that studies have shown suffer from disparities: African Americans, Appalachians, Asians and Hispanics. This grant will support the formation of a coordinating center to collect and analyze data and biospecimens from The OSUCCC – James network of collaborating recruitment sites across the United States.

Targeting Oncogenes for New Liver Cancer Drugs

Liver cancer is the third leading cause of cancer death in the United States and incidence rates are rising. The liver is designed to keep foreign substances out of the body, so developing drugs that effectively penetrate the liver and successfully target cancerous cells has been challenging. In this study, researchers will conduct preclinical tests to determine the effectiveness of new drugs that target two oncogenes—genes that promote cancer growth when highly expressed—along with a tumor-suppressing microRNA called miR-122, which is critical to maintaining normal liver function. Results from these studies could lead to a phase 1 clinical trial in liver cancer patients.

Understanding Molecular Crosstalk Driving Aggressive Breast Cancers

Research suggests that two molecular pathways in particular play important roles in breast cancer development and how it is spreads, but little is known about the molecular conversations and the chain of events that lead to breast cancer growth and metastasis. A better understanding of this molecular crosstalk could help scientists identify points in the pathway to intervene and put the brakes on cancer development. This project seeks to further characterize the role of proteins in the two-targeted pathways to better understand breast cancer growth, blood vessel formation and tumor spread. This information is especially critical for the development of new therapies in triple-negative breast cancers.

Brain Inflammation and Depression and Anxiety in Breast Cancer Patients

Breast cancer survivors commonly experience depression and anxiety—particularly when undergoing chemotherapy. Inflammatory changes in the brain could be a primary cause of these symptoms. This OSUCCC – James team will study whether reducing inflammation in the brain using a readily available and well-tolerated drug called minocycline reduces depression and anxiety during chemotherapy. This study will be conducted in up to 30 postmenopausal women receiving chemotherapy for breast cancer at the Stefanie Spielman Comprehensive Breast Center.

Digital Image Analysis, Targeted Therapies for Glioblastomas

Glioblastomas are the most common and deadly of primary brain tumors. Despite aggressive treatment, glioblastoma patients live an average of 15 months. In this project, OSUCCC-James researchers are developing advanced image analysis techniques to help guide critical decisions in patient treatment before and after brain surgery. This technology could also guide personalized treatment options, based on the specific molecular characteristics of each patient’s tumor.  Current imaging technologies make it difficult to distinguish between a cancer recurrence and treatment affected by chemotherapy and radiation. The goal of this study is to determine whether computerized image analysis combined with advanced protein analysis can significantly improve diagnostic accuracy and identify potential biomarkers that might help personalize treatment for each patient and provide insights into drug resistance.

Tools for Discovery

Pelotonia funds have helped bring new laboratories on line in Ohio State’s Biomedical Research Tower and have supported the purchase of scientific instrumentation.

Technology purchased in the past year includes:
• REES Enterprise Environmental Monitoring System
• Sciclone NGS (Next Generation Sequencing) Workstation
• Diagenode IPStar Compact for epigenetic applications

This instrumentation and other Pelotonia-funded equipment are accessible to and will benefit the research of more than 300 cancer investigators at the OSUCCC — James in the coming years.

Bringing the Best to Ohio State

Over the past five years, funds raised by Pelotonia have helped recruit to Ohio State and retain some of the brightest minds in cancer research. Among them in 2013, are two world-renowned senior cancer researchers; Raphael E. Pollock , MD, PhD, is a globally respected cancer surgeon, researcher and educator of physicians-in-training. Dr. Pollock is a professor and director of the Division of Surgical Oncology at Ohio State, and he serves as chief of surgical services of the OSUCCC – James. He came to Ohio State after 31 years at The University of Texas MD Anderson Cancer Center; and Vinay Puduvalli, MBBS, is a noted authority on developing therapies for patients with brain and spine malignancies using a combined approach of targeted therapies, innovative clinical trial designs and rational combinations of anticancer agents. Dr. Puduvalli, who serves as professor and director of the Division of Neuro-Oncology in the Department of Neurological Surgery, was also recruited to Ohio State from The University of Texas MD Anderson Cancer Center.

To read the full 2013 Pelotonia Investment report, click here. To learn more about the OSUCCC-James please visit